PARP inhibitors for hereditary breast cancer with germline BRCA mutation

被引：0

作者：

Im, Seock-Ah ^{[1
]}

机构：

[1] Seoul Natl Univ, Canc Res Inst, Dept Internal Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.05.426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PSY8-3

引用

页码：S423 / S423

页数：1

共 50 条

[11] Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1
Ponce, J.
Vigil, C.
Araujo, J. M.
Castaneda, C.
Calderon, G.
Buleje, J. L.
Acosta, O.
Danos, P.
Huaman, F.
Guevara-Fujita, M. L.
Aguilar, A.
Pinto, J. A.
Gomez, H. L.
Fujita, R.
CANCER RESEARCH, 2017, 77
[12] Cancer frequency in BRCA mutation families with hereditary breast and ovarian cancer
Cajal, Teresa Ramon y
Capdevila, Jaume
Carrera, Gemma
Villanueva, Rafael
Puig, Teresa
Gich, Ignasi
Diez, Orland
Alonso, M. Carmen
Barnadas, Agusti
ANNALS OF ONCOLOGY, 2006, 17 : 275 - 275
[13] Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Keung, Man Yee
Wu, Yanyuan
Badar, Francesca
Vadgama, Jaydutt V.
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
[14] Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation
Ain, Quratul
O'Connell, Rachel L.
Swarnkar, Parinita
Mcveigh, Terri
George, Angela
Tasoulis, Marios K.
Gui, Gerald P. H.
Wiggins, Jennifer
Khan, Aadil A.
Krupa, Katherine D. C.
Barry, Peter A.
Banerjee, Susana
Rusby, Jennifer E.
EJSO, 2025, 51 (03):
[15] Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
Sharma, Priyanka
Klemp, Jennifer R.
Kimler, Bruce F.
Mahnken, Jonathan D.
Geier, Larry J.
Khan, Qamar J.
Elia, Manana
Connor, Carol S.
McGinness, Marilee K.
Mammen, Joshua M. W.
Wagner, Jamie L.
Ward, Claire
Ranallo, Lori
Knight, Catherine J.
Stecklein, Shane R.
Jensen, Roy A.
Fabian, Carol J.
Godwin, Andrew K.
BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (03) : 707 - 714
[16] Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
Priyanka Sharma
Jennifer R. Klemp
Bruce F. Kimler
Jonathan D. Mahnken
Larry J. Geier
Qamar J. Khan
Manana Elia
Carol S. Connor
Marilee K. McGinness
Joshua M. W. Mammen
Jamie L. Wagner
Claire Ward
Lori Ranallo
Catherine J. Knight
Shane R. Stecklein
Roy A. Jensen
Carol J. Fabian
Andrew K. Godwin
Breast Cancer Research and Treatment, 2014, 145 : 707 - 714
[17] Survival in hereditary breast cancer associated with germline mutations of BRCA2
Verhoog, LC
Brekelmans, CTM
Seynaeve, C
Dahmen, G
van Geel, AN
Bartels, CCM
Tilanus-Linthorst, MMA
Wagner, A
Devilee, P
Halley, DJJ
van den Ouweland, AMW
Meijers-Heijboer, EJ
Klijn, JGM
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3396 - 3402
[18] Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression
Delgado, L
Fernández, G
González, A
Bressac-de Paillerets, B
Gualco, G
Bombled, J
Cataldi, S
Sabini, G
Roca, R
Musé, IM
CANCER GENETICS AND CYTOGENETICS, 2002, 133 (01) : 24 - 28
[19] PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
Mehta, Prashant
Bothra, Sneha J.
ADVANCES IN GENETICS, VOL 108, 2021, 108 : 35 - 80
[20] Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations
Kandace P. McGuire
Douglas W. Arthur
Eleftherios P. Mamounas
Annals of Surgical Oncology, 2022, 29 : 6504 - 6507

← 1 2 3 4 5 →